Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563401 | 0.89 | ALDH1A1 (0.67) | MEN1KMT2AHPGDALDH1A1POLB | |
| SCHEMBL27179624 | 0.87 | BCHE (0.59) | MEN1KMT2AHPGDALDH1A1HTT | |
| SCHEMBL711991 | 0.85 | HPGD (0.63) | MEN1KMT2AHPGDALDH1A1POLB | |
| SCHEMBL8266867 | 0.84 | MEN1 (0.66) | MEN1KMT2AHPGDALDH1A1HTT | |
| SCHEMBL3563409 | 0.82 | ALDH1A1 (0.66) | MEN1KMT2AHPGDALDH1A1HTT | |
| SCHEMBL3559462 | 0.82 | LMNA (0.58) | MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL27181100 | 0.80 | MAPT (0.64) | MEN1KMT2AHPGDALDH1A1HTT | |
| SCHEMBL30926784 | 0.80 | MAPT (0.64) | MEN1KMT2AHPGDALDH1A1HTT | |
| SCHEMBL4709087 | 0.80 | MEN1 (0.84) | MEN1KMT2AHPGDALDH1A1HTT | |
| SCHEMBL29106437 | 0.79 | ALDH1A1 (0.61) | MEN1KMT2AHPGDALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2005030709-A1 | NOVEL SULFONE AMIDE DERIVATIVES CAPABLE OF INHIBITING BACE | LG LIFE SCIENCES LTD. (KR) | 2005-04-07 | — | — | WO | disclosed |
| US-4439444-A | HISTAMINE RECEPTOR ANTAGONISTS | SANOFI (FR) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | MEN1 2868/4885KMT2A 2502/4885HPGD 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.